Assets
| Type | Time | Amount | Unit |
|---|---|---|---|
| ifrs-full:Assets | 2017-12-31 | 124798838 | vDKK |
Revenue
| Type | Start date | End date | Amount | Unit |
|---|---|---|---|---|
| ifrs-full:Revenue | 2016-11-14 | 2017-12-31 | 317442873 | vDKK |
XML
See the xml submitted here:
XML: http://regnskaber.virk.dk/54008183/ZG9rdW1lbnRsYWdlcjovLzAzLzVhLzRjLzRjL2FhLzcxNWMtNDY4ZC05ZGUxLTdiMWFhYTA0OGY0Zg.xml
Separator
The full data:
<?xml version="1.0" encoding="UTF-8"?><!-- Version: 1.1.734.0 --><!-- Document created: 01-05-2018 11:51:08 --><!-- Created by: XBRL Wizard, EasyX --><xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:entry="http://xbrl.dcca.dk/entryBalanceSheetAccountFormIncomeStatementByNature" xmlns:gsd="http://xbrl.dcca.dk/gsd" xmlns:tax="http://xbrl.dcca.dk/tax" xmlns:tch="http://xbrl.dcca.dk/tch" xmlns:gen="http://xbrl.org/2008/generic" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:variable="http://xbrl.org/2008/variable" xmlns:eogs="http://xbrl.dcca.dk/eogs" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:dst="http://xbrl.dcca.dk/dst" xmlns:arr="http://xbrl.dcca.dk/arr" xmlns:valm="http://xbrl.org/2010/message/validation" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:msg="http://xbrl.org/2010/message" xmlns:fsa="http://xbrl.dcca.dk/fsa" xmlns:cmn="http://xbrl.dcca.dk/cmn" xmlns:label="http://xbrl.org/2008/label" xmlns:mrv="http://xbrl.dcca.dk/mrv" xmlns:sob="http://xbrl.dcca.dk/sob" xsi:schemaLocation="http://xbrl.org/2006/xbrldi http://www.xbrl.org/2006/xbrldi-2006.xsd">
<link:schemaRef xlink:type="simple" xlink:href="http://archprod.service.eogs.dk/taxonomy/20171001/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByNatureIncludingManagementsReviewStatisticsAndTax20171001.xsd"/>
<xbrli:context id="ctx1">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-11-14</xbrli:startDate>
<xbrli:endDate>2017-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx2">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-11-14</xbrli:startDate>
<xbrli:endDate>2017-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfExecutiveBoardDimension">
<cmn:memberOfBoardIdentifier>0</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx3">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-11-14</xbrli:startDate>
<xbrli:endDate>2017-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>0</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx4">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-11-14</xbrli:startDate>
<xbrli:endDate>2017-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx5">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-11-14</xbrli:startDate>
<xbrli:endDate>2017-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>2</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx6">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-11-14</xbrli:startDate>
<xbrli:endDate>2017-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfAuditorDimension">
<cmn:auditorIdentifier>0</cmn:auditorIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx7">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx8">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-11-14</xbrli:startDate>
<xbrli:endDate>2017-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>0</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx9">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-11-14</xbrli:startDate>
<xbrli:endDate>2017-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>1</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx10">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-11-14</xbrli:startDate>
<xbrli:endDate>2017-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="mrv:IdentificationOfKeyFigureOrFinancialRatioDimension">
<mrv:keyFigureOrFinancialRatioIdentifier>2</mrv:keyFigureOrFinancialRatioIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx11">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">38180045</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-11-14</xbrli:startDate>
<xbrli:endDate>2017-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="fsa:ResultDistributionDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:unit id="vDKK">
<xbrli:measure>iso4217:DKK</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="pure">
<xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit>
<fsa:ClassOfReportingEntity contextRef="ctx1">Regnskabsklasse C, stor virksomhed</fsa:ClassOfReportingEntity>
<gsd:ReportingPeriodStartDate contextRef="ctx1">2016-11-14</gsd:ReportingPeriodStartDate>
<gsd:ReportingPeriodEndDate contextRef="ctx1">2017-12-31</gsd:ReportingPeriodEndDate>
<sob:StatementByExecutiveAndSupervisoryBoards contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Statement by the Board of Directors and the Executive Board</td></tr></table></sob:StatementByExecutiveAndSupervisoryBoards>
<sob:IdentificationOfApprovedAnnualReport contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Today, the Board of Directors and the Executive Board have discussed and approved the Annual Report of Novo Nordisk Region Europe Pharmaceuticals A/S for the financial year as of the establishment of the Company 14 November 2016 - 31 December 2017.</td></tr></table></sob:IdentificationOfApprovedAnnualReport>
<sob:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table></sob:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement>
<sob:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2017 and of the results of the Company operations for the financial year as of the establishment of the Company 14 November 2016 - 31 December 2017.</td></tr></table></sob:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults>
<sob:ManagementsStatementAboutManagementsReview contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Further, in our opinion, the Management's review gives a true and fair review of the development in the Company operations and financial matters and the results of the Company operations and financial position.</td></tr></table></sob:ManagementsStatementAboutManagementsReview>
<sob:RecommendationForApprovalOfAnnualReportByGeneralMeeting contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">We recommend that the Annual Report be approved at the annual general meeting.</td></tr></table></sob:RecommendationForApprovalOfAnnualReportByGeneralMeeting>
<sob:PlaceOfSignatureOfStatement contextRef="ctx1" xml:lang="da">Copenhagen</sob:PlaceOfSignatureOfStatement>
<sob:DateOfApprovalOfAnnualReport contextRef="ctx1">2018-03-12</sob:DateOfApprovalOfAnnualReport>
<arr:IndependentAuditorsReportsAudit contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Independent auditor's report</td></tr></table></arr:IndependentAuditorsReportsAudit>
<arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">To the shareholders of Novo Nordisk Region Europe Pharmaceuticals A/S</td></tr></table></arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements>
<arr:OpinionOnAuditedFinancialStatements contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Opinion</td></tr><tr><td colspan="1">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2017 and of the results of the Companyâs operations and cash flows for the financial year 1 January - 31 December 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan="1">We have audited the Financial Statements of Novo Nordisk Region Europe Pharmaceuticals A/S for the financial year 1 January - 31 December 2017, which comprise income statement, balance sheet, statement of changes in equity, cash flow statement and notes, including a summary of significant accounting policies (âthe Financial Statementsâ).</td></tr></table></arr:OpinionOnAuditedFinancialStatements>
<arr:DescriptionOfQualificationsOfAuditedFinancialStatements contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Basis for opinion</td></tr><tr><td colspan="1">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the âAuditorâs responsibilities for the audit of the Financial Statementsâ section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table></arr:DescriptionOfQualificationsOfAuditedFinancialStatements>
<arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Statement on the Management's review</td></tr><tr><td colspan="1">Management is responsible for Managementâs Review.</td></tr><tr><td colspan="1">Our opinion on the Financial Statements does not cover Managementâs Review, and we do not express any form of assurance conclusion thereon.</td></tr><tr><td colspan="1">In connection with our audit of the Financial Statements, our responsibility is to read Managementâs Review and, in doing so, consider whether Managementâs Review is materially inconsistent with the Financial Statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.</td></tr><tr><td colspan="1">Moreover, it is our responsibility to consider whether Managementâs Review provides the information required under the Danish Financials Statements Act.</td></tr><tr><td colspan="1">Based on the work we have performed, in our view, Managementâs Review is in accordance with the Financial Statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement in Managementâs Review.</td></tr></table></arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements>
<arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Management's responsibilities for the Financial Statements</td></tr><tr><td colspan="1">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan="1">In preparing the Financial Statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the Financial Statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table></arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements>
<arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Auditor's responsibilities for the audit of the Financial Statements</td></tr><tr><td colspan="1">Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.</td></tr><tr><td colspan="1">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also</td></tr><tr><td colspan="1">Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan="1">Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Companyâs internal control.</td></tr><tr><td colspan="1">Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan="1">Conclude on the appropriateness of Managementâs use of the going concern basis of accounting in preparing the Financial Statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Companyâs ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditorâs report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditorâs report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan="1">Evaluate the overall presentation, structure and contents of the Financial Statements, including the disclosures, and whether the Financial Statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan="1">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table></arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed>
<arr:SignatureOfAuditorsPlace contextRef="ctx1" xml:lang="da">Hellerup</arr:SignatureOfAuditorsPlace>
<arr:SignatureOfAuditorsDate contextRef="ctx1">2018-03-12</arr:SignatureOfAuditorsDate>
<gsd:NameOfReportingEntity contextRef="ctx1" xml:lang="da">Novo Nordisk Region Europe Pharmaceuticals A/S</gsd:NameOfReportingEntity>
<gsd:AddressOfReportingEntityPostCodeIdentifier contextRef="ctx1" xml:lang="da">2300</gsd:AddressOfReportingEntityPostCodeIdentifier>
<gsd:AddressOfReportingEntityDistrictName contextRef="ctx1" xml:lang="da">København S</gsd:AddressOfReportingEntityDistrictName>
<gsd:AddressOfReportingEntityStreetName contextRef="ctx1" xml:lang="da">Ãrestads Boulevard</gsd:AddressOfReportingEntityStreetName>
<gsd:AddressOfReportingEntityStreetBuildingIdentifier contextRef="ctx1" xml:lang="da">108</gsd:AddressOfReportingEntityStreetBuildingIdentifier>
<gsd:IdentificationNumberCvrOfReportingEntity contextRef="ctx1">38180045</gsd:IdentificationNumberCvrOfReportingEntity>
<gsd:DateOfFoundationOfReportingEntity contextRef="ctx1">2016-11-14</gsd:DateOfFoundationOfReportingEntity>
<gsd:RegisteredOfficeOfReportingEntity contextRef="ctx1" xml:lang="da">Copenhagen</gsd:RegisteredOfficeOfReportingEntity>
<gsd:PredingReportingPeriodEndDate contextRef="ctx1">2017-12-31</gsd:PredingReportingPeriodEndDate>
<gsd:TelephoneNumberOfReportingEntity contextRef="ctx1" xml:lang="da">+45 35 35 00 02</gsd:TelephoneNumberOfReportingEntity>
<gsd:NameAndSurnameOfChairmanOfGeneralMeeting contextRef="ctx1" xml:lang="da">Karoline Enodden</gsd:NameAndSurnameOfChairmanOfGeneralMeeting>
<gsd:DateOfGeneralMeeting contextRef="ctx1">2018-04-25</gsd:DateOfGeneralMeeting>
<fsa:InformationOnReportingClassOfEntity contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">The annual report of Novo Nordisk Region Europe Pharmaceuticals A/S for 2016/17 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to medium-sized reporting class C entities.</td></tr></table></fsa:InformationOnReportingClassOfEntity>
<fsa:ExplanationOfNotDisclosingCashFlowsStatements contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Omission of a cash flow statement</td></tr><tr><td colspan="1">With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared. The Company's cash flows are reflected in the consolidated cash flow statement for the higher-ranking parent company Novo Nordisk A/S.</td></tr></table></fsa:ExplanationOfNotDisclosingCashFlowsStatements>
<fsa:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Basis of recognition and measurement</td></tr><tr><td colspan="1">The Financial Statements have been preparedunder the historical cost method.</td></tr><tr><td colspan="1">Revenues are recognised in the income statementa s earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised cost are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan="1">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan="1">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan="1">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan="1">Recognition and measurement take into account predictable losses and risks occurring before the presentation of the Annual Report which confirm or invalidate affairs and conditions existing at the balance sheet date.</td></tr><tr><td colspan="1">Reporting currency</td></tr><tr><td colspan="1">The financial statements are presented in Danish kroner (DKK).</td></tr></table></fsa:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies>
<fsa:DescriptionOfMethodsOfForeignCurrencies contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Foreign currency translation</td></tr><tr><td colspan="1">On initial recognition, transactions denominated in foreign currencies are translated at the exchange rate at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and the date of payment are recognised in the income statement as financial income or financial expenses.</td></tr><tr><td colspan="1">Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rate at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the most recent financial statements is recognised in the income statement as financial income or financial expenses.</td></tr></table></fsa:DescriptionOfMethodsOfForeignCurrencies>
<fsa:DescriptionOfMethodsOfLeases contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Leases</td></tr><tr><td colspan="1">All lease contracts are operational lease commitments. Payments on operational lease commitments are measured in the income statement as per the leasing period.</td></tr></table></fsa:DescriptionOfMethodsOfLeases>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Revenue</td></tr><tr><td colspan="1">Income from the rendering of services is recognised as revenue as the services are rendered. All income is related to invoiced service fees to Novo Nordisk A/S which consist of the actual expenses including a mark-up.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCostOfSales contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Cost of sales</td></tr><tr><td colspan="1">Cost of sales includes the cost of external services used in generating the year's revenue.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCostOfSales>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Other external expenses</td></tr><tr><td colspan="1">Other external expenses include the year's expenses relating to the Company's core activities, including expenses relating to sales, marketing, administration, premises, IT, payments under operating leases, etc.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEmployeeBenefitExpense contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Staff costs</td></tr><tr><td colspan="1">Staff costs include wages and salaries, including compensated absence and pension to the Company's employees, as well as other social security contributions, etc. The item is net of refunds from public authorities.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEmployeeBenefitExpense>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Financial income and expenses</td></tr><tr><td colspan="1">Financial income and expenses are recognised in the income statements at the amounts that concern the financial year. Net financials include interest income and expenses as well as allowances and surcharges under the advance-payment-of-tax scheme, etc.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Tax</td></tr><tr><td colspan="1">Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.</td></tr><tr><td colspan="1">The Company and its Danish group entities are jointly taxed. The total Danish income tax charge is allocated between profit/loss-making Danish entities in proportion to their taxable income (full absorption).</td></tr><tr><td colspan="1">Jointly taxed entities entitled to a tax refund are reimbursed by the management company based on the rates applicable to interest allowances, and jointly taxed entities which have paid too little tax pay a surcharge according to the rates applicable to interest surcharges to the management company.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Property, plant and equipment</td></tr><tr><td colspan="1">Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment>
<fsa:DescriptionOfMethodsOfImpairmentLossesAndDepreciation contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="2">Depreciation</td></tr><tr><td colspan="2">The item comprises amortisation/depreciation and impairment of property, plant and equipment.</td></tr><tr><td colspan="2">The basis of depreciation, which is calculated as cost less any residual value, is depreciated on a straight line basis over the expected useful life. The expected useful lives of the assets are as follows</td></tr><tr><td>Fixtures and fittings, other plant and equipment</td><td>10 years</td></tr><tr><td colspan="2">The residual value is determined at the time of acquisition and are reassessed every year. Where the residual value exceeds the carrying amount of the asset, no further depreciation charges are recognised. In case of changes in the residual value, the effect on the depreciation charges is recognised prospectively as a change in accounting estimates.</td></tr></table></fsa:DescriptionOfMethodsOfImpairmentLossesAndDepreciation>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Receivables</td></tr><tr><td colspan="1">Receivables are measured at amortised cost.</td></tr><tr><td colspan="1">An impairment loss is recognised if there is objective evidence that a receivable or a group of receivables is impaired. If there is objective evidence that an individual receivable has been impaired, an impairment loss is recognised on an individual basis.</td></tr><tr><td colspan="1">Receivables in respect of which there is no objective evidence of individual impairment are tested for objective evidence of impairment on a portfolio basis. The portfolios are primarily based on the debtors' domicile and credit ratings in line with the Company's risk management policy. The objective evidence applied to portfolios is determined based on historical loss experience.</td></tr><tr><td colspan="1">Impairment losses are calculated as the difference between the carrying amount of the receivables and the present value of the expected cash flows, including the realisable value of any collateral received. The effective interest rate for the individual receivable or portfolio is used as discount rate.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeAssets contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Prepayments</td></tr><tr><td colspan="1">Prepayments recognised under "Assets" comprise prepaid expenses regarding subsequent financial reporting years.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeAssets>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Cash</td></tr><tr><td colspan="1">Cash comprise cash and short term securities which are readily convertible into cash and subject only to minor risks of changes in value.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Income taxes</td></tr></table><br><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Deferred tax is measured according to the liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. However, deferred tax is not recognised on temporary differences relating to goodwill which is not deductible for tax purposes and on office premises and other items where temporary differences, apart from business combinations, arise at the date of acquisition without affecting either profit/loss for the year or taxable income. Where alternative tax rules can be applied to determine the tax base, deferred tax is measured based on Management's intended use of the asset or settlement of the liability, respectively.</td></tr><tr><td colspan="1">Deferred tax is measured according to the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the expected value of their utilisation; either as a set-off against tax on future income or as a set-off against deferred tax liabilities in the same legal tax entity. Changes in deferred tax due to changes in the tax rate are recognised in the income statement.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax>
<fsa:DescriptionOfMethodsOfCurrentTaxReceivablesAndLiabilities contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Current tax payables and receivables are recognised in the balance sheet as the estimated income tax charge for the year, adjusted for prior-year taxes and tax paid on account.</td></tr></table></fsa:DescriptionOfMethodsOfCurrentTaxReceivablesAndLiabilities>
<fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Liabilities</td></tr><tr><td colspan="1">Financial liabilities are recognised at the date of borrowing at the net proceeds received less transaction costs paid. On subsequent recognition, financial liabilities are measured at amortised cost, corresponding to the capitalised value, using the effective interest rate. Accordingly, the difference between the proceeds and the nominal value is recognised in the income statement over the term of the loan. Financial liabilities also include the capitalised residual lease liability in respect of finance leases.</td></tr><tr><td colspan="1">Other liabilities are measured at net realisable value.</td></tr></table></fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions>
<fsa:DescriptionOfMethodsOfStatingKeyFiguresAndFinancialRatiosIncludedInManagementReview contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Financial ratios</td></tr><tr><td colspan="1">Financial ratios are calculated in accordance with the Danish Finance Society's guidelines on the calculation of financial ratios.</td></tr><tr><td colspan="1">The financial ratios stated under "Financial highlights" have been calculated as follows</td></tr><tr><td colspan="1">Operating margin: Operating profit x 100 / Revenue</td></tr><tr><td colspan="1">Gross margin ratio: Gross margin x 100 / Revenue</td></tr><tr><td colspan="1">EBITDA-margin: EBITDA / Revenue x 100</td></tr><tr><td colspan="1">Return on assets: Profit/loss from operating activites x 100 / Average assets</td></tr><tr><td colspan="1">Current ratio: Current assets x 100 / Current liabilities</td></tr><tr><td colspan="1">Return on equity: Profit/loss for the year after tax x 100 / Average equity</td></tr><tr><td colspan="1">Equity ratio: Equity, year-end x 100 / Total equity and liabilities, year-end</td></tr></table></fsa:DescriptionOfMethodsOfStatingKeyFiguresAndFinancialRatiosIncludedInManagementReview>
<mrv:ManagementsReview contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Management's review</td></tr><tr><td colspan="1">Business review</td></tr><tr><td colspan="1">In October 2016, Executive Management in Novo Nordisk A/S approved the recommendation to relocate the European regional office from Zürich to Copenhagen as of 1 January 2017 by establishing a new legal entity named: Novo Nordisk Region Europe Pharmaceuticals A/S (hereafter NNRE Pharmaceuticals A/S). Around 25 employee moved/was hired from the beginning of the year and approximately 40 employees have been hired during the year.</td></tr><tr><td colspan="1">The purpose of NNRE Pharmaceuticals A/S is to act as a regional office and support sales and marketing activities in the Novo Nordisk affiliates in Europe in order to launch and supply best in class products. The treatment areas consist of diabetes, obesity, growth and bleeding disorders as well as hormone replacement treatment. NNRE Pharmaceuticals A/S also supports the European affiliates in regards to IT with a virtual setup where IT personnel is located in affiliates and reporting to the IT management located in Copenhagen.</td></tr><tr><td colspan="1">Unusual matters having affected the financial statements</td></tr><tr><td colspan="1">The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2016/17 have not been affected by any unusual events.</td></tr><tr><td colspan="1">Financial review</td></tr><tr><td colspan="1">In 2016/17, the Company's revenue amounted to DKK 317,442,873. The income statement for 2016/17 shows a profit of DKK 5,378,615, and the balance sheet at 31 December 2017 shows equity of DKK 5,878,615.</td></tr><tr><td colspan="1">Special risks</td></tr><tr><td colspan="1">NNRE Pharmaceuticals A/S is a service company in the Novo Nordisk group and Novo Nordisk A/S bears all the risks for launches and research &amp; development. All costs, both internal and external, in NNRE Pharmaceuticals A/S are (due to a service contract) invoiced to Novo Nordisk A/S as service fee including a mark-up for internal costs.</td></tr><tr><td colspan="1">Events after the balance sheet date</td></tr><tr><td colspan="1">No events materially affecting the Company's financial position have occurred subsequent to the financial year-end.</td></tr><tr><td colspan="1">Outlook</td></tr><tr><td colspan="1">NNRE Pharmaceuticals A/S are expected to continue the support to the affiliates in Europe in 2018 with high focus on the launch of new products. Revenue and profit/loss for the coming year is expected to be in the same range as for 2017 due to the service contract with Novo Nordisk A/S.</td></tr></table></mrv:ManagementsReview>
<fsa:Revenue contextRef="ctx1" unitRef="vDKK" decimals="0">317442873</fsa:Revenue>
<fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx1" unitRef="vDKK" decimals="0">6887961</fsa:ProfitLossFromOrdinaryOperatingActivities>
<fsa:ResultsFromNetFinancials contextRef="ctx1" unitRef="vDKK" decimals="0">198430</fsa:ResultsFromNetFinancials>
<fsa:ProfitLoss contextRef="ctx1" unitRef="vDKK" decimals="0">5378615</fsa:ProfitLoss>
<fsa:InvestmentInPropertyPlantAndEquipment contextRef="ctx1" unitRef="vDKK" decimals="0">1768507</fsa:InvestmentInPropertyPlantAndEquipment>
<mrv:OperatingMargin contextRef="ctx1" unitRef="pure" decimals="3">0.022</mrv:OperatingMargin>
<mrv:GrossMargin contextRef="ctx1" unitRef="pure" decimals="3">0.352</mrv:GrossMargin>
<mrv:ReturnOnEquity contextRef="ctx1" unitRef="pure" decimals="3">0.915</mrv:ReturnOnEquity>
<mrv:EquityRatio contextRef="ctx1" unitRef="pure" decimals="3">0.047</mrv:EquityRatio>
<fsa:AverageNumberOfEmployees contextRef="ctx1" unitRef="pure" decimals="3">52.000</fsa:AverageNumberOfEmployees>
<mrv:DescriptionOfKeyFiguresAndFinancialRatios contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Financial ratios are calculated in accordance with the Danish Finance Society's recommendations on the calculation of financial ratios. For terms and definitions, please see the accounting policies.</td></tr></table></mrv:DescriptionOfKeyFiguresAndFinancialRatios>
<fsa:CostOfSales contextRef="ctx1" unitRef="vDKK" decimals="0">86263108</fsa:CostOfSales>
<fsa:OtherExternalExpenses contextRef="ctx1" unitRef="vDKK" decimals="0">119547116</fsa:OtherExternalExpenses>
<fsa:GrossResult contextRef="ctx1" unitRef="vDKK" decimals="0">111632649</fsa:GrossResult>
<fsa:EmployeeBenefitsExpense contextRef="ctx1" unitRef="vDKK" decimals="0">104659624</fsa:EmployeeBenefitsExpense>
<fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss contextRef="ctx1" unitRef="vDKK" decimals="0">85064</fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss>
<fsa:OtherFinanceIncome contextRef="ctx1" unitRef="vDKK" decimals="0">564250</fsa:OtherFinanceIncome>
<fsa:OtherFinanceExpenses contextRef="ctx1" unitRef="vDKK" decimals="0">365820</fsa:OtherFinanceExpenses>
<fsa:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="ctx1" unitRef="vDKK" decimals="0">7086391</fsa:ProfitLossFromOrdinaryActivitiesBeforeTax>
<fsa:TaxExpenseOnOrdinaryActivities contextRef="ctx1" unitRef="vDKK" decimals="0">1707776</fsa:TaxExpenseOnOrdinaryActivities>
<fsa:StatementOfChangesInEquity contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="5" align="left" valign="middle" >Statement of changes in equity</td></tr><tr><td colspan="5"></td></tr><tr><td width="40%" colspan="2" align="left" valign="middle" >DKK</td><td width="17%" colspan="1" align="right" valign="middle" >Share capital</td><td width="23%" colspan="1" align="right" valign="middle" >Retained earnings</td><td width="20%" colspan="1" align="right" valign="middle" >Total</td></tr><tr><td width="40%" colspan="2" align="left" valign="middle" >Cash payments concerning formation of enterprise</td><td width="17%" align="right" valign="middle" > 500.000 </td><td width="23%" align="right" valign="middle" >0</td><td width="20%" align="right" valign="middle" > 500.000 </td></tr><tr><td width="28%" colspan="1" align="left" valign="middle" >Transfer, see "Appropriation of profit"</td><td width="12%" align="right" valign="middle" >12</td><td width="17%" align="right" valign="middle" >0</td><td width="23%" align="right" valign="middle" > 5.378.615 </td><td width="20%" align="right" valign="middle" > 5.378.615 </td></tr><tr><td width="40%" colspan="2" align="left" valign="middle" >Equity at 31 December 2017</td><td width="17%" align="right" valign="middle" > 500.000 </td><td width="23%" align="right" valign="middle" > 5.378.615 </td><td width="20%" align="right" valign="middle" > 5.878.615 </td></tr></table></fsa:StatementOfChangesInEquity>
<fsa:DisclosureOfEmployeeBenefitsExpense contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="2" align="left" valign="middle" >Staff costs and incentive programmes</td></tr><tr><td width="50%" ></td><td width="50%" colspan="1" align="right" valign="middle" >2016/17</td></tr><tr><td width="50%" colspan="1" align="left" valign="middle" >DKK</td><td width="50%" colspan="1" align="right" valign="middle" >14 months</td></tr><tr><td width="50%" colspan="1" align="left" valign="middle" >Wages/salaries</td><td width="50%" align="right" valign="middle" >80.026.676</td></tr><tr><td width="50%" colspan="1" align="left" valign="middle" >Pensions</td><td width="50%" align="right" valign="middle" >4.668.386</td></tr><tr><td width="50%" colspan="1" align="left" valign="middle" >Other staff costs</td><td width="50%" align="right" valign="middle" >19.964.562</td></tr><tr><td width="50%" ></td><td width="50%" align="right" valign="middle" >104.659.624</td></tr><tr><td width="50%" colspan="1" align="left" valign="middle" >Average number of full-time employees</td><td width="50%" align="right" valign="middle" >52</td></tr><tr><td colspan="2"></td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" >By reference to section 98b(3), (ii), of the Danish Financial Statements Act, remuneration to Management is not disclosed.</td></tr><tr><td colspan="2"></td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" >Incentive programmes</td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" >Management participates in Novo Nordisk A/Sâs incentive programme. Novo Nordisk A/S bears the cost.</td></tr><tr><td colspan="2"></td></tr></table></fsa:DisclosureOfEmployeeBenefitsExpense>
<fsa:DisclosureOfOtherFinanceIncome contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="2" align="left" valign="middle" >Financial income</td></tr><tr><td width="50%" colspan="1" align="left" valign="middle" >Interest income, group entities</td><td width="50%" align="right" valign="middle" >375.702</td></tr><tr><td width="50%" colspan="1" align="left" valign="middle" >Other financial income</td><td width="50%" align="right" valign="middle" >188.548</td></tr><tr><td width="50%" ></td><td width="50%" align="right" valign="middle" >564.250</td></tr></table></fsa:DisclosureOfOtherFinanceIncome>
<fsa:DisclosureOfOtherFinanceExpenses contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="2" align="left" valign="middle" >Financial expenses</td></tr><tr><td width="50%" colspan="1" align="left" valign="middle" >Interest expenses, group entities</td><td width="50%" align="right" valign="middle" >152.371</td></tr><tr><td width="50%" colspan="1" align="left" valign="middle" >Other financial expenses</td><td width="50%" align="right" valign="middle" >213.449</td></tr><tr><td width="50%" ></td><td width="50%" align="right" valign="middle" >365.820</td></tr></table></fsa:DisclosureOfOtherFinanceExpenses>
<fsa:DisclosureOfTaxExpenses contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="2" align="left" valign="middle" >Tax for the year</td></tr><tr><td width="50%" colspan="1" align="left" valign="middle" >Estimated tax charge for the year</td><td width="50%" align="right" valign="middle" >3.791.148</td></tr><tr><td width="50%" colspan="1" align="left" valign="middle" >Deferred tax adjustments in the year</td><td width="50%" align="right" valign="middle" >-2.083.372</td></tr><tr><td width="50%" ></td><td width="50%" align="right" valign="middle" >1.707.776</td></tr></table></fsa:DisclosureOfTaxExpenses>
<fsa:DisclosureOfPropertyPlantAndEquipment contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="2" align="left" valign="middle" >Property, plant and equipment</td></tr><tr><td width="50%" colspan="1" align="left" valign="middle" >DKK</td><td width="50%" colspan="1" align="right" valign="middle" >Fixtures and fittings, other plant and equipment</td></tr><tr><td width="50%" colspan="1" align="left" valign="middle" >Additions</td><td width="50%" align="right" valign="middle" >1.768.507</td></tr><tr><td width="50%" colspan="1" align="left" valign="middle" >Cost at 31 December 2017</td><td width="50%" align="right" valign="middle" >1.768.507</td></tr><tr><td width="50%" colspan="1" align="left" valign="middle" >Depreciation</td><td width="50%" align="right" valign="middle" >85.064</td></tr><tr><td width="50%" colspan="1" align="left" valign="middle" >Impairment losses and depreciation at 31 December 2017</td><td width="50%" align="right" valign="middle" >85.064</td></tr><tr><td width="50%" colspan="1" align="left" valign="middle" >Carrying amount at 31 December 2017</td><td width="50%" align="right" valign="middle" >1.683.443</td></tr><tr><td colspan="2"></td></tr></table></fsa:DisclosureOfPropertyPlantAndEquipment>
<fsa:InformationOnCurrentDeferredTaxAssets contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="2" align="left" valign="middle" >Deferred tax</td></tr><tr><td width="50%" colspan="1" align="left" valign="middle" >DKK</td><td width="50%" colspan="1" align="right" valign="middle" >2016/17</td></tr><tr><td width="50%" colspan="1" align="left" valign="middle" >Other deferred tax</td><td width="50%" align="right" valign="middle" >-2.083.372</td></tr><tr><td width="50%" colspan="1" align="left" valign="middle" >Deferred tax at 31 December 2017</td><td width="50%" align="right" valign="middle" >-2.083.372</td></tr><tr><td colspan="2"></td></tr></table></fsa:InformationOnCurrentDeferredTaxAssets>
<fsa:ExplanationOfPrepayments contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="1" align="left" valign="middle" >Prepayments</td></tr><tr><td width="100%" colspan="1" align="left" valign="middle" >Prepayments include accrual of expenses relating to subsequent financial years, including payments for market data, congresses and software licenses.</td></tr><tr><td colspan="1"></td></tr></table></fsa:ExplanationOfPrepayments>
<fsa:DisclosureOfOtherProvisions contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="1" align="left" valign="middle" >Other provisions</td></tr><tr><td width="100%" colspan="1" align="left" valign="middle" >Other provisions comprise provisions for anniversary bonuses, totalling DKK 1,024,084.</td></tr><tr><td colspan="1"></td></tr></table></fsa:DisclosureOfOtherProvisions>
<fsa:DisclosureOfContingentLiabilities contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="2" align="left" valign="middle" >Contractual obligations and contingencies, etc.</td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" >Other contingent liabilities</td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" >The Company is jointly taxed with its parent, Novo Nordisk A/S, which acts as management company, and is jointly and severally liable with other jointly taxed group entities for payment of income taxes for the income year 2017 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 14 November 2016.</td></tr><tr><td colspan="2"></td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" >Other financial obligations</td></tr><tr><td width="100%" colspan="2" align="left" valign="middle" >Other rent and lease liabilities</td></tr><tr><td width="50%" colspan="1" align="left" valign="middle" >Rent and lease liabilities</td><td width="50%" align="right" valign="middle" >22.060.585</td></tr><tr><td colspan="2"></td></tr></table></fsa:DisclosureOfContingentLiabilities>
<fsa:InformationOnRelatedEntities contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td width="100%" colspan="3" align="left" valign="middle" >Related parties</td></tr><tr><td width="100%" colspan="3" align="left" valign="middle" >Novo Nordisk Region Europe Pharmaceuticals A/S' related parties comprise the following</td></tr><tr><td width="100%" colspan="3" align="left" valign="middle" >Parties exercising control</td></tr><tr><td width="33%" colspan="1" align="left" valign="middle" >Related party</td><td width="33%" colspan="1" align="right" valign="middle" >Domicile</td><td width="34%" colspan="1" align="right" valign="middle" >Basis for control</td></tr><tr><td width="33%" colspan="1" align="left" valign="middle" >Novo Nordisk Region Europe A/S</td><td width="33%" colspan="1" align="right" valign="middle" >Novo Alle 1, 2880 Bagsværd</td><td width="34%" colspan="1" align="right" valign="middle" >Participating interest</td></tr><tr><td width="33%" ></td><td width="33%" ></td><td width="34%" colspan="1" align="right" valign="middle" >Shareholders' agreement</td></tr><tr><td width="33%" ></td><td width="33%" ></td><td width="34%" colspan="1" align="right" valign="middle" >Participating interest</td></tr><tr><td colspan="3"></td></tr><tr><td width="100%" colspan="3" align="left" valign="middle" >Information about consolidated financial statements</td></tr><tr><td colspan="3"></td></tr><tr><td width="33%" colspan="1" align="left" valign="middle" >Parent Domicile</td><td width="33%" colspan="1" align="left" valign="middle" >Domicile</td><td width="34%" colspan="1" align="left" valign="middle" >Requisitioning of the parent company's consolidated financial statements</td></tr><tr><td width="33%" colspan="1" align="left" valign="middle" >Novo Nordisk A/S</td><td width="33%" colspan="1" align="left" valign="middle" >Novo Alle 1, 2880 Bagsværd</td><td width="34%" colspan="1" align="left" valign="middle" >www.novonordisk.dk</td></tr><tr><td colspan="3"></td></tr></table></fsa:InformationOnRelatedEntities>
<gsd:InformationOnTypeOfSubmittedReport contextRef="ctx1">Ã
rsrapport</gsd:InformationOnTypeOfSubmittedReport>
<gsd:IdentificationNumberCvrOfSubmittingEnterprise contextRef="ctx1">38180045</gsd:IdentificationNumberCvrOfSubmittingEnterprise>
<gsd:NameOfSubmittingEnterprise contextRef="ctx1" xml:lang="da">Novo Nordisk Region Europe Pharmaceuticals A/S</gsd:NameOfSubmittingEnterprise>
<gsd:AddressOfSubmittingEnterpriseStreetAndNumber contextRef="ctx1" xml:lang="da">Ãrestads Boulevard 108</gsd:AddressOfSubmittingEnterpriseStreetAndNumber>
<gsd:AddressOfSubmittingEnterprisePostcodeAndTown contextRef="ctx1" xml:lang="da">2300 København S</gsd:AddressOfSubmittingEnterprisePostcodeAndTown>
<cmn:TypeOfAuditorAssistance contextRef="ctx1">Revisionspåtegning</cmn:TypeOfAuditorAssistance>
<cmn:NameAndSurnameOfMemberOfExecutiveBoard contextRef="ctx2" xml:lang="da">Steffen Thejls</cmn:NameAndSurnameOfMemberOfExecutiveBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx3" xml:lang="da">Ole F. Ramsby</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx3" xml:lang="da">Chairman</cmn:TitleOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx4" xml:lang="da">Matt Joseph Regan</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx5" xml:lang="da">Karsten Munk Knudsen</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameOfAuditFirm contextRef="ctx6" xml:lang="da">PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab</cmn:NameOfAuditFirm>
<cmn:IdentificationNumberCvrOfAuditFirm contextRef="ctx6">33771231</cmn:IdentificationNumberCvrOfAuditFirm>
<cmn:NameAndSurnameOfAuditor contextRef="ctx6" xml:lang="da">Mads Melgaard</cmn:NameAndSurnameOfAuditor>
<cmn:DescriptionOfAuditor contextRef="ctx6" xml:lang="da">State Authorised Public Accountant</cmn:DescriptionOfAuditor>
<cmn:IdentificationNumberOfAuditor contextRef="ctx6">mne34354</cmn:IdentificationNumberOfAuditor>
<gsd:AddressOfAuditorStreetName contextRef="ctx6" xml:lang="da">Strandvejen</gsd:AddressOfAuditorStreetName>
<gsd:AddressOfAuditorStreetBuildingIdentifier contextRef="ctx6" xml:lang="da">44</gsd:AddressOfAuditorStreetBuildingIdentifier>
<gsd:AddressOfAuditorPostCodeIdentifier contextRef="ctx6" xml:lang="da">2900</gsd:AddressOfAuditorPostCodeIdentifier>
<gsd:AddressOfAuditorDistrictName contextRef="ctx6" xml:lang="da">Hellerup</gsd:AddressOfAuditorDistrictName>
<fsa:Assets contextRef="ctx7" unitRef="vDKK" decimals="0">124798838</fsa:Assets>
<fsa:Equity contextRef="ctx7" unitRef="vDKK" decimals="0">5878615</fsa:Equity>
<fsa:FixturesFittingsToolsAndEquipment contextRef="ctx7" unitRef="vDKK" decimals="0">1683443</fsa:FixturesFittingsToolsAndEquipment>
<fsa:PropertyPlantAndEquipment contextRef="ctx7" unitRef="vDKK" decimals="0">1683443</fsa:PropertyPlantAndEquipment>
<fsa:NoncurrentAssets contextRef="ctx7" unitRef="vDKK" decimals="0">1683443</fsa:NoncurrentAssets>
<fsa:ShorttermReceivablesFromGroupEnterprises contextRef="ctx7" unitRef="vDKK" decimals="0">95493314</fsa:ShorttermReceivablesFromGroupEnterprises>
<fsa:CurrentDeferredTaxAssets contextRef="ctx7" unitRef="vDKK" decimals="0">2083372</fsa:CurrentDeferredTaxAssets>
<fsa:DeferredIncomeAssets contextRef="ctx7" unitRef="vDKK" decimals="0">3943050</fsa:DeferredIncomeAssets>
<fsa:ShorttermReceivables contextRef="ctx7" unitRef="vDKK" decimals="0">101519736</fsa:ShorttermReceivables>
<fsa:CashAndCashEquivalents contextRef="ctx7" unitRef="vDKK" decimals="0">21595659</fsa:CashAndCashEquivalents>
<fsa:CurrentAssets contextRef="ctx7" unitRef="vDKK" decimals="0">123115395</fsa:CurrentAssets>
<fsa:ContributedCapital contextRef="ctx7" unitRef="vDKK" decimals="0">500000</fsa:ContributedCapital>
<fsa:RetainedEarnings contextRef="ctx7" unitRef="vDKK" decimals="0">5378615</fsa:RetainedEarnings>
<fsa:OtherProvisions contextRef="ctx7" unitRef="vDKK" decimals="0">1024084</fsa:OtherProvisions>
<fsa:Provisions contextRef="ctx7" unitRef="vDKK" decimals="0">1024084</fsa:Provisions>
<fsa:TradePayables contextRef="ctx7" unitRef="vDKK" decimals="0">10442849</fsa:TradePayables>
<fsa:PayablesToGroupEnterprises contextRef="ctx7" unitRef="vDKK" decimals="0">33729601</fsa:PayablesToGroupEnterprises>
<fsa:TaxPayablesToGroupEnterprises contextRef="ctx7" unitRef="vDKK" decimals="0">3291148</fsa:TaxPayablesToGroupEnterprises>
<fsa:OtherPayables contextRef="ctx7" unitRef="vDKK" decimals="0">70432541</fsa:OtherPayables>
<fsa:LiabilitiesOtherThanProvisions contextRef="ctx7" unitRef="vDKK" decimals="0">117896139</fsa:LiabilitiesOtherThanProvisions>
<fsa:LiabilitiesAndEquity contextRef="ctx7" unitRef="vDKK" decimals="0">124798838</fsa:LiabilitiesAndEquity>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx8" xml:lang="da">EBITDA-margin</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx8" unitRef="pure" decimals="3">0.022</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx9" xml:lang="da">Return on assets</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx9" unitRef="pure" decimals="3">0.055</mrv:ValueOfKeyFigureOrFinancialRatio>
<mrv:NameOfKeyFigureOrFinancialRatio contextRef="ctx10" xml:lang="da">Current ratio</mrv:NameOfKeyFigureOrFinancialRatio>
<mrv:ValueOfKeyFigureOrFinancialRatio contextRef="ctx10" unitRef="pure" decimals="3">1.044</mrv:ValueOfKeyFigureOrFinancialRatio>
<fsa:ProfitLoss contextRef="ctx11" unitRef="vDKK" decimals="0">5378615</fsa:ProfitLoss>
</xbrli:xbrl>